GTC
AKBA icon

Ghost Tree Capital’s Akebia Therapeutics AKBA Stock Holding History

Ghost Tree Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-250,000
Closed -$628K – 46
2020
Q3 		$628K Buy
+250,000
New +$2.19M 0.18% 43
2016
Q4 		– Sell
-300,000
Closed -$2.71M – 71
2016
Q3 		$2.71M Buy
+300,000
New +$2.55M 0.44% 61

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Ghost Tree Capital's AKBA Position: Q4 2020 in Review

Ghost Tree Capital sold out of Akebia Therapeutics (AKBA) in Q4 2020, closing a stake of 250,000 shares — an estimated $628K sold.

Ghost Tree Capital first reported a position in AKBA in Q3 2016 and held it in 2 quarters. The position peaked at $2.71M in Q3 2016. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

  • Ghost Tree Capital reported no remaining Akebia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Ghost Tree Capital sold 250,000 Akebia Therapeutics shares in Q4 2020, an estimated $628K.
  • Ghost Tree Capital first reported a position in Akebia Therapeutics in Q3 2016 and held it in 2 quarters.
  • Ghost Tree Capital's Akebia Therapeutics position peaked at $2.71M in Q3 2016.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on Ghost Tree Capital's 13F filing for Q4 2020, filed 16 Feb 2021.